A review of onabotulinumtoxinA (Botox).
نویسندگان
چکیده
OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.
منابع مشابه
The First Case Report of a Systemic Allergy to OnabotulinumtoxinA (Botox) in a Healthy Patient.
UNLABELLED To the authors' knowledge, this is the first report of an allergy to onabotulinumtoxinA. The 43-year-old woman experienced severe itching after injection of Botox and Juvéderm. Results of prick and patch testing confirmed a T-cell-mediated allergy to Botox. This case can aid in the evaluation of suspected allergies to Botox. LEVEL OF EVIDENCE 5.
متن کاملORDERING BOTOX® STORAGE OF BOTOX® BOTOX® (onabotulinumtoxinA) Ordering and Storage Instructions
Lack of Interchangeability Between Botulinum Toxin Products The potency Units of BOTOX® are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of BOTOX® cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other speci...
متن کاملvon Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder
A 67-year-old female with refractory OAB was treated with intradetrusor Botox. She subsequently developed multiple papillary bladder lesions with tissue biopsy showing Von Brunn's nests. Von Brunn's nests are benign bladder lesions similar in appearance to a rare urothelial tumor called Nested Variant of Urothelial Carcinoma (NVUC). It is critical that patients with these findings undergo evalu...
متن کاملOnabotulinumtoxinA (Botox®) and AbobotulinumtoxinA (Dysport®) Esansiyel Blefarospazm Tedavisinde Botox® ve Dysport® un Uzun Dönem Sonuçları
Objective:To compare the clinical characteristics and outcomes of patients with blepharospasm who were treated with OnabotulinumtoxinA (Botox®) and AbobotulinumtoxinA (Dysport®). Methods: A total of 100 eyes of 78 patients who were diagnosed with blepharospasm were evaluated during a retrospective, randomized, parallel group study. The severity of spasm, eyelid closing force, and functional vis...
متن کاملDifficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity.
OBJECTIVES Intravesical injection of onabotulinumtoxinA (i.e. Botox) provides effective treatment for overactive bladder. However, treatment-related adverse events (AEs) remain problems. This study investigated the effect of AEs after onabotulinumtoxinA injection on the success rate for idiopathic detrusor overactivity (IDO). METHODS A total of 174 patients who received the first single intra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Aesthetic surgery journal
دوره 33 1 Suppl شماره
صفحات -
تاریخ انتشار 2013